Related references
Note: Only part of the references are listed.Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
Stephane de Botton et al.
BLOOD ADVANCES (2023)
Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia
William Villiers et al.
NATURE COMMUNICATIONS (2023)
Retinoic acid receptor regulation of decision-making for cell differentiation
Geoffrey Brown
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)
Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
Huan Song et al.
BLOOD (2022)
Retinoic acid, RARs and early development
Marie Berenguer et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2022)
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)
Huai-Yu Wang et al.
BLOOD CANCER JOURNAL (2022)
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Maxi Wass et al.
LEUKEMIA (2021)
A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia
Yun Tan et al.
BLOOD (2021)
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Mina M. Tayari et al.
CLINICAL CANCER RESEARCH (2021)
Retinoids in hematology: a timely revival?
Marie-Claude Geoffroy et al.
BLOOD (2021)
Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions
Nadiya Bayeva et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
Laura Cicconi et al.
LEUKEMIA (2020)
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Shanshan Pei et al.
CANCER DISCOVERY (2020)
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids
Daniela Hernandez et al.
LEUKEMIA (2020)
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation
Roberto Ravasio et al.
SCIENCE ADVANCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML
Alexander J. Ambinder et al.
FRONTIERS IN ONCOLOGY (2020)
Knockout of Cyp26a1 and Cyp26b1 during postnatal life causes reduced lifespan, dermatitis, splenomegaly, and systemic inflammation in mice
Jessica M. Snyder et al.
FASEB JOURNAL (2020)
FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias
Cecile Esnault et al.
BLOOD (2019)
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse
Licia Iaccarino et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia
Michael R. McKeown et al.
HAEMATOLOGICA (2019)
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes
Kimberly N. Smitheman et al.
HAEMATOLOGICA (2019)
Retinoid-Sensitive Epigenetic Regulation of the Hoxb Cluster Maintains Normal Hematopoiesis and Inhibits Leukemogenesis
Pengxu Qian et al.
CELL STEM CELL (2018)
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
Hong-Hu Zhu et al.
LANCET ONCOLOGY (2018)
Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia
Hikaru Hattori et al.
PLOS ONE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells
Geoffrey Brown et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2017)
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
Yasmin Abaza et al.
BLOOD (2017)
Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse
Annette Fasan et al.
HAEMATOLOGICA (2017)
Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions
Jing Jing et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Michael R. McKeown et al.
CANCER DISCOVERY (2017)
Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse
Annette Fasan et al.
HAEMATOLOGICA (2017)
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid
Han J. M. P. Verhagen et al.
BLOOD (2016)
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Helena Boutzen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Targeted Therapy Alone for Acute Promyelocytic Leukemia
Francesco Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An ATRActive future for differentiation therapy in AML
Daniel E. Johnson et al.
BLOOD REVIEWS (2015)
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
David Sanford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Alan K. Burnett et al.
LANCET ONCOLOGY (2015)
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
Harry J. Iland et al.
LANCET HAEMATOLOGY (2015)
All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment
Meng Su et al.
PLOS ONE (2015)
Induction of CYP26A1 by Metabolites of Retinoic Acid: Evidence That CYP26A1 Is an Important Enzyme in the Elimination of Active Retinoids
Ariel R. Topletz et al.
MOLECULAR PHARMACOLOGY (2015)
The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid
Birgit Steinmetz et al.
CELL CYCLE (2014)
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial
Katsuji Shinagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Hong-Hu Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment
Roisin M. Connolly et al.
CLINICAL CANCER RESEARCH (2013)
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies
Julien Ablain et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells
L. C. Y. Chee et al.
LEUKEMIA (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling
Gabriel Ghiaur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia
Robert E. Gallagher et al.
BLOOD (2012)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas
Arthur P. Chou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
Emi Goto et al.
BLOOD (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Retinoid pathway and cancer therapeutics
Nathan Bushue et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Alan K. Burnett et al.
BLOOD (2010)
PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia
Kankan Wang et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
PML-RARα/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
Joost H. A. Martens et al.
CANCER CELL (2010)
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PML-RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
E. Schachter-Tokarz et al.
LEUKEMIA (2010)
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Xiao-Wei Zhang et al.
SCIENCE (2010)
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Richard F. Schlenk et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies
Lisa Berglund et al.
MOLECULAR & CELLULAR PROTEOMICS (2008)
Arsenic degrades PML or PML - RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway
Valerie Lallemand-Breitenbach et al.
NATURE CELL BIOLOGY (2008)
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Rihab Nasr et al.
NATURE MEDICINE (2008)
Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1
Shireen Saleque et al.
MOLECULAR CELL (2007)
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma -: a study of the United Kingdom Children's Cancer Study Group
G. J. Veal et al.
BRITISH JOURNAL OF CANCER (2007)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Donald W. Milligan et al.
BLOOD (2006)
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series
Apostolia-Maria Tsimberidou et al.
LEUKEMIA & LYMPHOMA (2006)
Overview of retinoid metabolism and function
Rune Blomhoff et al.
JOURNAL OF NEUROBIOLOGY (2006)
Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells
B Ozpolat et al.
LEUKEMIA & LYMPHOMA (2005)
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia
PZ Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death
M Osanai et al.
MOLECULAR PHARMACOLOGY (2005)
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor
A Insinga et al.
EMBO JOURNAL (2004)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression
P Westervelt et al.
BLOOD (2003)
All-trans retinoic acid in acute promyelocytic leukemia:: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
MS Tallman et al.
BLOOD (2002)
The role of retinoids and retinoic acid receptors in normal hematopoiesis
SJ Collins
LEUKEMIA (2002)
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
L Di Croce et al.
SCIENCE (2002)
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results
M Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Positive and negative regulation of granulopoiesis by endogenous RARα
P Kastner et al.
BLOOD (2001)
Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism
JA White et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation
M Vickers et al.
LEUKEMIA (2000)
Share Paper
